Mitigating the toxic effects of anticancer immunotherapy

Nature Reviews Clinical Oncology

Volumn 11, Issue 2, 2014, Pages 91-99

  Gangadhar, Tara C ^a   Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, MONOCLONAL; CANCER VACCINES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS;

EID: 84895904745     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.245     Document Type: Review

References (76)

1. Atkins, M. B. et al. High-dose recombinant interleukin therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
2. Margolin, K. A. et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumo rs: Analysis of toxicity and management guidelines. J. Clin. Oncol. 7, 486-498 (1989).
3. Kirkwood, J. M. et al. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10, 1670-1677 (2004).
4. Eggermont, A. M. et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Fin al results of EORTC 18991, a randomised phase III trial. Lancet 372, 117-126 (2008).
5. Mocellin, S. et al. Interferon adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J. Natl Cancer Inst. 102, 493-501 (2010).
6. Kirkwood, J. M. et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J. Clin. Oncol. 20, 3703-3718 (2002).
7. Melero, I., Hervas-Stubbs S., Glennie, M., Pardoll, D. M. & Chen, L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7, 95-106 (2007).
8. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
9. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
10. Ribas, A. et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675206. J. Clin. Oncol. 23, 8968-8977 (2005).
11. Ribas, A. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616-622 (2013).
12. Khattri, R., Auger , J. A., Griffin, M. D., Sharpe, A. H. & Bluestone, J. A. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J. Immunol. 162, 5784-5791 (1999).
13. Wolchok, J. D. & Saenger, Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13 (Suppl. 4), 2-9 (2008).
14. Attia, P. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043-6053 (2005).
15. Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377 (2003).
16. Downey, S. G. et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13 (22 Pt 1), 6681-6688 (2007).
17. Weber, J. S. Kähler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691-2697 (2012).
18. Di Giacomo, A. M., Biagio li, M. & Maio, M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin. Oncol. 37, 499-507 (2010).
19. Beck, K. E. et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen. J. Clin. Oncol. 24, 2283-2289 (2006).
20. Phan, G. Q., Weber, J. S. & Sondak, V. K. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: Surgical issues. Ann. Surg. Oncol. 15, 3014-3021 (2008).
21. Bristol-Myers Squibb. YERVOY™ (ipilimumab): Immune-mediated Adverse Reaction Management Guide [online], https://www.hcp.yervoy.com/pdf/rems- management-guide.pdf (2011).
22. Weber, J. et al. A randomized, do uble-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15, 5591-5598 2009).
23. Kim, K. W. et al. Ipilimumab-associated colitis: CT findings. Am. J. Roentgenol. 200, 468-474 (2013).
24. Robinson, M. R. et al. Cytotoxic T lymphocyte-associated antigen blockade in patients with metastatic melanoma: A new cause of uveitis. J. Immunother. 27, 478-479 (2004).
25. Corsello, S. M. et al. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98, 1361-1375 (2013).
26. Hamnvik, O. P., Larsen, P. R. & Marqusee, E. Thyroid dysfunction from antineoplastic agents. J. Natl Cancer Inst. 103, 1572-1587 (2011).
27. Blansfield, J. A. et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and rena l cancer. J. Immunother. 28, 593-598 (2005).
28. Wilgenhof, S. & Neyns, B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann. Oncol. 22, 991-993 (2011).
29. YERVOY® (ipilimumab) package insert [online], http://packageinserts. bms.com/pi/pi-yervoy.pdf (Bristol-Myers Squibb, 2013).
30. Robert, C. et al. Efficacy and safety of retreatme nt with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin. Cancer Res. 19, 2232-2239 (2013).
31. Wolchok, J. D. et al. Ipilimumab e fficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials. Cancer Immun. 10, 9-14 (2010).
32. Wei, F. et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc. Natl Acad. Sci. USA 110, e2480-e2489 (2013).
33. Blackburn, S. D. et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009).
34. Riley, J. L. & June, C. H. The road to recovery: Translating PD-1 biology into clinical benefit. Trends Immunol. 28, 48-50 (2007).
35. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
36. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
37. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
38. Ribas, A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366, 2517-2519 (2012).
39. Sznol, M. et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. J. Clin. Oncol. 31 (Suppl.), CRA9006 (2013).
40. Hamid, O. et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in pati ents with locally advanced or metastatic melanoma (mM) [abstract]. J. Clin. Oncol. 31 (Suppl.), a9010 (2013).
41. Chacon, J. A. et al. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8 + melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS ONE 8, e60031 (2013).
42. Melero, I. et al. A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) [abstract]. J. Clin. Oncol. 31 (Suppl.), TPS3107 (2013).
43. Sznol, M. e t al. Phase I study of BMS-663513 a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) [abstract]. J. Clin. Oncol. 26 (Suppl.), a3007 (2008).
44. Ascierto, P. A. et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37, 508-516 (2010).
45. Hwu, W. J. Targeted therapy for metastatic melanoma: From bench to bedside. HemOnc Today [online], http://www.hemonctoday.com/article.aspxrid=65856 (2010).
46. Glaude, R. P. et al. The CD40 agonist antibody CP-870, 893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-h u mice. Cancer Immunol. Immunother. 60, 1009-1017 (2011).
47. Vonderheide, R. H. et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25, 876-883 (2007).
48. Vonderheide, R. H. et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2, e23033 (2013).
49. Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
50. Vonderheide, R. H. & Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035-1043 (2013).
51. Kalos, M. & June, C. H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49-60 (2013).
52. Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557 (2011).
53. Vonderheide, R. H. & June, C. H. A translational bridge to cancer immunotherapy: Exploiting costimulation and target antigens for active and passive T cell immunotherapy. Immunol. Res. 27, 341-356 (2003).
54. Kalos, M., Levine, B. L. & Porter, D. L. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with adv anced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
55. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
56. Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
57. Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012).
58. Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
59. Brentjens, R. et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666-668 (2010).
60. Till, B. G. et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results. Blood 119, 3940-3950 (2012).
61. Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050-6056 (2011).
62. Zhong, S. et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl Acad. Sci. USA 110, 6973-6978 (2013).
63. Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133-151 (2013).
64. Cameron, B. J. et a l. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).
65. Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863-871 (2013).
66. Morgan, R. et al. Case report of a serious adverse event following the ad ministration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851 (2010).
67. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
68. Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and in terferon- production. Blood 90, 2541-2548 (1997).
69. Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol. 25, 9543-9553 (2005).
70. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
71. Wilmott, J. S. et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386-1394 (2012).
72. Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. Hepatotoxicity w ith combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013).
73. Hodi, F. S. et al. Multicenter, randomized phase II trial of GM-CSF plus ipilimumab (Ipi) versus Ipi alone in metas tatic melanoma: E1608 [abstract]. J. Clin. Oncol. 31 (Suppl.), CRA9007 (2013).
74. Beatty, G. L. et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2, 3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies [abstract]. J. C lin. Oncol. 31 (Suppl.), a3025 (2013).
75. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
76. Riley, J. L. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N. Engl. J. Med. 369, 187-189 (2013).